Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parabacteroides distasonis
- Development stage
- Preclinical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Parabacteroides distasonis is a Gram-negative anaerobic bacterium that is a natural resident of the human gut microbiota. It is being developed as a next-generation probiotic or live biotherapeutic product (LBP) for various diseases. The bacterium itself is the active ingredient, exerting its effects by producing a range of metabolites, including nicotinic acid, succinate, and short-chain fatty acids (SCFAs). These metabolites interact with host systems by targeting pathways such as the intestinal GPR109a receptor and PPARα signaling. Additionally, P. distasonis is recognized for its immunomodulatory properties; outer membrane vesicles (Pd-OMVs) derived from the bacterium are being explored as potential immunostimulants for cancer immunotherapy by modulating CXCL10 and CD8+ T cell responses. Research institutions are investigating its therapeutic potential in metabolic and gastrointestinal diseases, including obesity, type 2 diabetes, inflammatory bowel disease, and various cancers.
- Other names
- P. distasonis
02
Targets
CXCL10 (C-X-C Motif Chemokine Ligand 10)FXR (Farnesoid x-activated receptor)HCAR2 (Hydroxycarboxylic acid receptor 2)GLP1R (GLP-1R)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on Parabacteroides distasonis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Parabacteroides distasonis.